Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A

Molecular Metabolism

Volumn 4, Issue 4, 2015, Pages 265-276

  Rajan, Sindhu ^a,b   Dickson, Lorna M ^a,b   Mathew, Elizabeth ^a,b   Orr, Caitlin M O ^a,b,c   Ellenbroek, Johanne H ^a,b   Philipson, Louis H ^a,b,c   Wicksteed, Barton ^a,b,c  

^a The University of Chicago ^*  (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

GLP 1 receptor; Hyperglycemia; Protein kinase A; Small ubiquitin related modifier

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 8; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EXENDIN 4; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL SURFACE; CHRONIC DISEASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; HYPERGLYCEMIA; IMMUNOBLOTTING; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

RODENTIA;

EID: 84924342324     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.01.010     Document Type: Article

References (56)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705.
2. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & Therapeutics 2007, 113(3):546-593.
3. Furman B., Pyne N., Flatt P., O'Harte F. Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. The Journal of Pharmacy and Pharmacology 2004, 56(12):1477-1492.
4. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359(9309):824-830.
5. Bunck M.C., Diamant M., Corner A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32(5):762-768.
6. Gallwitz B., Guzman J., Dotta F., Guerci B., Simo R., Basson B.R., et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012, 379(9833):2270-2278.
7. Stumvoll M., Fritsche A., Haring H.U. Clinical characterization of insulin secretion as the basis for genetic analyses. Diabetes 2002, 51(Suppl 1):S122-S129.
8. Kjems L.L., Holst J.J., Volund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52(2):380-386.
9. Fritsche A., Stefan N., Hardt E., Haring H., Stumvoll M. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 2000, 43(7):852-858.
10. Knop F.K., Vilsboll T., Hojberg P.V., Larsen S., Madsbad S., Volund A., et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes 2007, 56(8):1951-1959.
11. Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes & Metabolism 2013, 39(3):195-201.
12. Shao Y., Yuan G., Feng Y., Zhang J., Guo X. Early liraglutide treatment is better in glucose control, beta-cell function improvement and mass preservation in db/db mice. Peptides 2014, 52:134-142.
13. Hojberg P.V., Zander M., Vilsboll T., Knop F.K., Krarup T., Volund A., et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008, 51(4):632-640.
14. Hojberg P.V., Vilsboll T., Rabol R., Knop F.K., Bache M., Krarup T., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52(2):199-207.
15. Hansen K.B., Vilsboll T., Bagger J.I., Holst J.J., Knop F.K. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. The Journal of Clinical Endocrinology & Metabolism 2012, 97(4):1363-1370.
16. Lynn F.C., Thompson S.A., Pospisilik J.A., Ehses J.A., Hinke S.A., Pamir N., et al. Anovel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. Faseb Journal 2003, 17(1):91-93.
17. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56(6):1551-1558.
18. Biden T.J., Schmitz-Peiffer C., Burchfield J.G., Gurisik E., Cantley J., Mitchell C.J., et al. The diverse roles of protein kinase C in pancreatic beta-cell function. Biochemical Society Transactions 2008, 36(Pt 5):916-919.
19. Widmann C., Dolci W., Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Molecular Endocrinology 1996, 10(1):62-75.
20. Widmann C., Dolci W., Thorens B. Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. The Journal of Biological Chemistry 1996, 271(33):19957-19963.
21. Baggio L.L., Kim J.G., Drucker D.J. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization invitro but does not attenuate GLP-1R-dependent glucose homeostasis invivo. Diabetes 2004, 53(Suppl 3):S205-S214.
22. Roed S.N., Wismann P., Underwood C.R., Kulahin N., Iversen H., Cappelen K.A., et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Molecular and Cellular Endocrinology 2013, 382(2):938-949.
23. Tian Y., Laychock S.G. Protein kinase C and calcium regulation of adenylyl cyclase in isolated rat pancreatic islets. Diabetes 2001, 50(11):2505-2513.
24. Ramos L.S., Zippin J.H., Kamenetsky M., Buck J., Levin L.R. Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. The Journal of General Physiology 2008, 132(3):329-338.
25. Zippin J.H., Chen Y., Straub S.G., Hess K.C., Diaz A., Lee D., et al. CO2/HCO3(-)- and calcium-regulated soluble adenylyl cyclase as a physiological ATP sensor. The Journal of Biological Chemistry 2013, 288(46):33283-33291.
26. Rajan S., Torres J., Thompson M.S., Philipson L.H. SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. American Journal of Physiology. Endocrinology and Metabolism 2012, 302(6):E714-E723.
27. Orellana S.A., Amieux P.S., Zhao X., McKnight G.S. Mutations in the catalytic subunit of the cAMP-dependent protein kinase interfere with holoenzyme formation without disrupting inhibition by protein kinase inhibitor. The Journal of Biological Chemistry 1993, 268(10):6843-6846.
28. Woodford T.A., Correll L.A., McKnight G.S., Corbin J.D. Expression and characterization of mutant forms of the type I regulatory subunit of cAMP-dependent protein kinase. The effect of defective cAMP binding on holoenzyme activation. The Journal of Biological Chemistry 1989, 264(22):13321-13328.
29. Dickson L.M., Lingohr M.K., McCuaig J., Hugl S.R., Snow L., Kahn B.B., et al. Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). The Journal of Biological Chemistry 2001, 276(24):21110-21120.
30. Landa L.R., Harbeck M., Kaihara K., Chepurny O., Kitiphongspattana K., Graf O., et al. Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. The Journal of Biological Chemistry 2005, 280(35):31294-31302.
31. Clegg C.H., Correll L.A., Cadd G.G., McKnight G.S. Inhibition of intracellular cAMP-dependent protein kinase using mutant genes of the regulatory type I subunit. The Journal of Biological Chemistry 1987, 262(27):13111-13119.
32. Permutt A., Chirgwin J., Giddings S., Kakita K., Rotwein P. Insulin biosynthesis and diabetes mellitus. Clinical Biochemistry 1981, 14(5):230-236.
33. Newgard C.B., McGarry J.D. Metabolic coupling factors in pancreatic beta-cell signal transduction. Annual Review of Biochemistry 1995, 64:689-719.
34. Goodge K.A., Hutton J.C. Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic beta-cell. Seminars in Cell & Developmental Biology 2000, 11(4):235-242.
35. Delmeire D., Flamez D., Hinke S.A., Cali J.J., Pipeleers D., Schuit F. Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1. Diabetologia 2003, 46(10):1383-1393.
36. Dou H., Wang C., Wu X., Yao L., Zhang X., Teng S., et al. Calcium influx activates adenylyl cyclase 8 for sustained insulin secretion in rat pancreatic beta cells. Diabetologia 2014, 58(2):324-333.
37. Klinger S., Poussin C., Debril M.B., Dolci W., Halban P.A., Thorens B. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 2008, 57(3):584-593.
38. Drucker D.J. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013, 62(10):3316-3323.
39. Chepurny O.G., Kelley G.G., Dzhura I., Leech C.A., Roe M.W., Dzhura E., et al. PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM in human islets of Langerhans. American Journal of Physiology. Endocrinology and Metabolism 2010, 298(3):E622-E633.
40. Fehmann H.C., Jiang J., Schweinfurth J., Wheeler M.B., Boyd A.E., Goke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 1994, 15(3):453-456.
41. Agbor T.A., Cheong A., Comerford K.M., Scholz C.C., Bruning U., Clarke A., et al. Small ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxia. The Journal of Biological Chemistry 2011, 286(6):4718-4726.
42. Giri R., Yeh H.H., Wu C.H., Liu H.S. SUMO-1 overexpression increases RbAp46 protein stability and suppresses cell growth. Anticancer Research 2008, 28(6A):3749-3756.
43. Cox B., Briscoe J., Ulloa F. SUMOylation by Pias1 regulates the activity of the hedgehog dependent gli transcription factors. PLoS One 2010, 5(8):e11996.
44. Han L., Pan Y., Wang B. Small ubiquitin-like modifier (SUMO) modification inhibits GLI2 protein transcriptional activity invitro and invivo. The Journal of Biological Chemistry 2012, 287(24):20483-20489.
45. Li X., Vadrevu S., Dunlop A., Day J., Advant N., Troeger J., et al. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochemical Journal 2010, 428(1):55-65.
46. Fehmann H.C., Jiang J., Pitt D., Schweinfurth J., Goke B. Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. Pancreas 1996, 13(3):273-282.
47. Larsen J., Hylleberg B., Ng K., Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24(8):1416-1421.
48. Gromada J., Dissing S., Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms. British Journal of Pharmacology 1996, 118(3):769-775.
49. Alarcon C., Wicksteed B., Rhodes C.J. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006, 49(12):2920-2929.
50. Wong W., Scott J.D. AKAP signalling complexes: focal points in space and time. Nature Reviews. Molecular Cell Biology 2004, 5(12):959-970.
51. Herberg F.W., Maleszka A., Eide T., Vossebein L., Tasken K. Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding. Journal of Molecular Biology 2000, 298(2):329-339.
52. Alto N.M., Soderling S.H., Hoshi N., Langeberg L.K., Fayos R., Jennings P.A., et al. Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(8):4445-4450.
53. Song W.J., Seshadri M., Ashraf U., Mdluli T., Mondal P., Keil M., et al. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metabolism 2011, 13(3):308-319.
54. D'Alessio D.A. Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?. Diabetes 2010, 59(7):1572-1574.
55. Dupre J., Behme M.T., McDonald T.J. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism 2004, 89(7):3469-3473.
56. Kielgast U., Holst J.J., Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes 2011, 60(5):1599-1607.